Dopamine D2L Receptor Knockout Mouse Provides a Unique Model System for Studying the Functions of D2L and D2S

  • Yanyan Wang
  • Rong Xu
  • Toshikuni Sasaoka
  • Emma-B. Sankoorikal
Part of the Advances in Behavioral Biology book series (ABBI, volume 53)


Dopamine receptors are classified into two categories: D1-like receptors (including the D1 and D5 subtypes), and D2-like receptors (including the D2, D3, and D4 subtypes). These classifications are based on both gene structure and pharmacological criteria.1 Among D2-like receptors, D2 is the most abundant form in the brain, with expression levels 10- to 100-fold higher than those of D3 or D4. Two isoforms of the D2 receptor, termed D2L (long form) and D2S (short form), have been identified in the brain. Little is known about the distinct functions of either D2 isoform. No selective pharmacological agents are currently available. We have generated mice lacking the D2L receptor (D2L-/-), but expressing a functional D2S receptor. Thus, the mouse expressing purely D2S (D2L-/-) should allow us to identify a D2 ligand relatively selective for D2S, to assess the effects of drugs on neurons expressing only D2S, and to examine the effects of drugs on behaviors mediated by D2S. Because D2L is the predominant D2 isoform expressed in wild-type (WT) mice, the comparisons made between D2L-/- and WT mice will reveal novel information regarding the functions of D2L. Here, we attempted to investigate the distinct functional roles of D2L and D2S, using D2L-/- mouse as a model system and a combination of approaches.


Nissl Staining Distinct Functional Role Unique Model System Pharmacological Criterion Selective Pharmacological Agent 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    D. R. Sibley, F. J. Monsma Jr., and Y. Shen, Molecular neurobiology of dopaminergic receptors, Int. Rev. Neurobiol. 35, 391–415 (1993).PubMedCrossRefGoogle Scholar
  2. 2.
    Y. Wang, R. Xu, T. Sasaoka, S. Tonegawa, M.-P. Kung, and E.-B. Sankoorikal, Dopamine D2 long receptor-deficient mice display alterations in striatum-dependent functions, J. Neurosci. 20, 8305–8314 (2000).PubMedGoogle Scholar
  3. 3.
    K.-L. Vukhac, E.-B. Sankoorikal, and Y. Wang, Dopamine D2L receptor- and age-related reduction in offensive aggression, Neuro Report 12, 1035–1038 (2001).Google Scholar
  4. 4.
    A. Usiello, J.-H. Baik, F. Rouge-Pont, R. Picetti, A. Dierich, M. LeMeur, P. V. Piazza, and E. Borrelli, Distinct functions of the two isoforms of dopamine D2 receptors. Nature 408, 199–203 (2000).PubMedCrossRefGoogle Scholar
  5. 5.
    Y. Wang and G. K. Aghajanian, Excitation of locus coeruleus neurons by vasoactive intestinal peptide: role of cAMP and protein kinase A, J. Neurosci. 10, 3335–3343 (1990).PubMedGoogle Scholar
  6. 6.
    M. Carlsson and A. Carlsson, Interactions between glutamatergic and monoaminergic systems within the basal ganglia — implications for schizophrenia and Parkinson’s disease, TINS 13, 274–276 (1990).Google Scholar
  7. 7.
    P. Seeman and H. H. M. Van Tol, Dopamine receptor pharmacology, Curr. Opin. Neurol. Neurosurg. 6, 602–608 (1993).PubMedGoogle Scholar
  8. 8.
    S. H. Snyder, Catecholamines in the brain as mediators of amphetamine psychosis, Arch. Gen. Psychiat. 27, 169–179 (1972).PubMedCrossRefGoogle Scholar
  9. 9.
    J. W. Langston, I. Irwin, and G. A. Ricaurte, Neurotoxins, Parkinsonism and Parkinson’s Disease, Pharmac. Ther. 32, 19–49 (1987).CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2002

Authors and Affiliations

  • Yanyan Wang
    • 1
  • Rong Xu
    • 1
  • Toshikuni Sasaoka
    • 2
  • Emma-B. Sankoorikal
    • 1
  1. 1.Department of PharmacologyUniversity of Pennsylvania School of MedicinePhiladelphiaUSA
  2. 2.National Institute of NeuroscienceTokyoJapan

Personalised recommendations